胰腺肿瘤Mn-DPDP增强MRI表现

Manifestations of Pancreatic Tumors on Mn-DPDP-Enhanced MR Imaging

目的 描述胰腺肿瘤Mn DPDP增强MRI表现。资料与方法 2 7例胰腺肿瘤患者中胰腺癌 2 2例 ,神经内分泌肿瘤 2例 ,囊腺瘤 1例 ,囊腺癌 2例。行SET1W、脂肪抑制FSET2 W及脂肪抑制SET1W和SPGRT1W平扫后 ,行Gd DTPA动态增强 ,次日按 0 .5ml/kg体重的剂量经肘静脉以 2～ 3ml/min的流率缓慢滴注Mn DPDP ,于给药结束后30min以及 2 4h行SET1W及SPGRT1W扫描。结果 在Mn DPDP增强后两种序列扫描图像上 2 2例胰腺癌和 2例神经内分泌肿瘤均无强化 ,囊腺癌和囊腺瘤实质部分有不确定轻度强化。结论 Mn DPDP增强后胰腺癌无强化 ,神经内分泌肿瘤及囊腺癌或瘤Mn DPDP增强MRI表现有待于更进一步研究。

Objective To describe Mn DPDP enhanced MRI manifestations of pancreatic tumors.Materials and Methods Twenty seven patients with pancreatic tumor were collected. The pancreatic lesions included adenocarcinoma (n=22), cystadenocarcinoma (n=2), cystadenoma (n=1) and neuroendocrinoma (n=2). SE T 1WI with and without fat saturation, fast SE T 2WI with fat saturation, and Gd DTPA enhanced dynamic scanning were carried out. On the next day, SE T 1WI and SPGR T 1WI were performed, which started at 30 min and 24 hrs after the end of intravenous infusion of Mn DPDP, respectively, with a dose of 0.5 ml/kg body weight and at a rate of 2～3 ml/s.Results On Mn DPDP enhanced MRI, no enhancement was seen in adenocarcinoma or neuroendocrinoma, while slight uncertain enhancement of the tumorous parenchyma was seen in cystadenocarcinoma and cystadenoma. Conclusion Pancreatic adenocarcinomas show no enhancement on Mn DPDP enhanced MRI. A further study is needed to clarify Mn DPDP enhanced MRI manifestations of pancreatic neuroendocrinoma, cystadenocarcinoma and cystadenoma.